Type 2 patients who received intensified treatment at first signs of microalbuminuria survived almost 8 years longer than those who did not.  Danish researchers used a cohort of 160 type 2 diabetes patients with microalbuminuria and found those in the intensive therapy group had 8.1 years longer median time to first cardiovascular event and a reduced risk for all microvascular complications, except for peripheral neuropathy, compared with the conventional therapy group. According to this study published online in Diabetologia, which included patients with type 2 diabetes and microalbuminuria, showed that early, intensified intervention in type 2 diabetes patients with microalbuminuria increased their lifespan, with patients more likely free from severe complications, according to the published study. Participants were randomly assigned to conventional therapy or an intensified, multifactorial treatment that included behavioral and pharmacological intervention. Of those 160 patients, 38 intensive-therapy patients and 55 conventional-therapy patients died during follow-up of 21.2 years (hazard ratio, 0.55). The average survival was a median of 7.9 years longer for patients in the intensive-therapy group versus the conventional-therapy group. The median time to first cardiovascular event was 8.1 years longer in the intensive-therapy group, and the risk for all microvascular complications was decreased in the intensive-therapy group with the exception of peripheral neuropathy.  In conclusion, from the results of the study, they found that intensified, multifactorial treatment of type 2 diabetes with microalbuminuria for 7.8 years compared with conventional treatment increased median life length by 7.9 years over 21.2 years of follow-up, and that these gained years were matched by years free from cardiovascular complications. — First online at Diabetologia August 16, 2016